piritrexim has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrows, LR; Gangjee, A; Kisliuk, RL; Queener, SF; Shi, J | 1 |
| Blum, MR; Clendeninn, NJ; Collier, MA; Everitt, BJ; Grebe, G; Johnson, NW; Mackars, A; Macklin, AW; Sigel, CW; Woolley, JL | 1 |
2 other study(ies) available for piritrexim and Experimental Neoplasms
| Article | Year |
|---|---|
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Folic Acid Antagonists; Fungal Proteins; Humans; Liver; Mice; Molecular Conformation; Neoplasms, Experimental; Oxidation-Reduction; Pneumocystis; Pneumocystis Infections; Protozoan Proteins; Pyrimidines; Rats; Structure-Activity Relationship; Toxoplasma | 1993 |
Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.
Topics: Animals; Behavior, Animal; Dogs; Folic Acid Antagonists; Heart; Metabolic Clearance Rate; Methotrexate; Mice; Muscle, Smooth; Neoplasms, Experimental; Pyrimidines; Rats; Solubility; Tissue Distribution; Tumor Cells, Cultured | 1987 |